- $2.1 BnWorld market, 2023
- $4.1 BnProjected, 2033
- 6.9%Growth a year (CAGR)
- 1,012Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$882 Mn
4.9% a year · 42% of the world -
2
China
$169 Mn
8.4% a year · 8% of the world -
3
Canada
$168 Mn
6.9% a year · 8% of the world -
4
Japan
$131 Mn
7.4% a year · 6.2% of the world -
5
Germany
$77 Mn
5.1% a year · 3.7% of the world -
6
France
$58 Mn
5.9% a year · 2.8% of the world -
7
UK
$55 Mn
4.9% a year · 2.6% of the world -
8
Brazil
$53 Mn
7.9% a year · 2.5% of the world -
9
Italy
$50 Mn
6.4% a year · 2.4% of the world -
10
Ecuador
$42 Mn
7.5% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
Spain
AustraliaAlzheimers Dignostic by country and region
India
Saudi Arabia
Mexico
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 32,077 papers since 2021
- Mn-doped dual-emission CdZnSe/Mn:ZnS quantum dots for self-calibrated ratiometric sensing of Alzheimer's disease biomarker. Analytica chimica acta, 2026
- CRISPR-enabled ultrasensitive surface-enhanced Raman scattering sensing platform for background-free detection of phosphorylated tau in Alzheimer's disease. Biosensors & bioelectronics, 2026
- A ratiometric dual-modal photoacoustic and near-infrared fluorescence probe for in vivo spatiotemporal mapping of butyrylcholinesterase in Alzheimer's disease. Talanta, 2026
- Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial. JMIR research protocols, 2026
- Sensitive detection of amyloid-β42 using a graphitic carbon nitride-boosted electrochemical peptide biosensor. Mikrochimica acta, 2026
Compare Alzheimers Dignostic side by side
Key companies in Alzheimers Dignostic
AbbVie
AC Immune (Switzerland)
AMARANTUS BIOSCIENCE HOLDINGS, INC.
Anavex Life Sciences Corp.
Eli Lilly and Company
AXON Neuroscience (Slovakia)
Sio Gene Therapies
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche
General Electric Company
Janssen Pharmaceuticals, Inc.
TauRx Pharmaceuticals Ltd
Quick answers
How big is the Alzheimers Dignostic market?
The world Alzheimers Dignostic market was worth about $2.1 Bn in 2023 and is projected to reach $4.1 Bn by 2033, growing 6.9% a year (CAGR).
Which country has the largest Alzheimers Dignostic market?
The US is the largest of the 24 countries we cover, at $882 Mn in 2023. India grows fastest, at 9.9% a year.
How many clinical trials are running in Alzheimers Dignostic?
ClinicalTrials.gov lists 1,012 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Alzheimers Dignostic?
PubMed lists about 32,077 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.